Teija Sainio

Mrs. Teija Sainio


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
TSTeija Sainio
Teija Sainio
JSJani Saunavaara
Jani Saunavaara
GKGaber Komar
Gaber Komar
SMSami Mattila
Sami Mattila
SOSaara Otonkoski
Saara Otonkoski
RSRoberto Blanco Sequeiros
Roberto Blanco Sequeiros
To investigate the feasibility of using an apparent diffusion coefficient (ADC) classification in predicting the technical outcome of magnetic resonance imaging-guided high-intensity focused ultras...

1 January 2020 in International Journal of Hyperthermia
Verified
Journal Article
Open access
SOSaara Otonkoski
Saara Otonkoski
TSTeija Sainio
Teija Sainio
GKGaber Komar
Gaber Komar
VSVisa Suomi
Visa Suomi
JSJani Saunavaara
Jani Saunavaara
KJKirsi Joronen
Kirsi Joronen
Uterine fibroids are the most common benign neoplasms in women. The administration of intravenous oxytocin is known to increase the efficacy of a non-invasive thermal ablation method (MR-HIFU) for ...

28 November 2018 in Journal of Therapeutic Ultrasound
Verified
Journal Article
Open access
PDF file
TSTeija Sainio
Teija Sainio
GKGaber Komar
Gaber Komar
JSJani Saunavaara
Jani Saunavaara
VSVisa Suomi
Visa Suomi
KJKirsi Joronen
Kirsi Joronen
RSRoberto Blanco Sequeiros
Roberto Blanco Sequeiros
Magnetic resonance guided high-intensity focused ultrasound (MR-HIFU) therapy is not feasible in all patients with uterine fibroids because of limiting anatomical factors such as scar tissue, bowel loops or other obstacles in the sonication path. These may prevent the treatment or limit the treatment window, and therefore, also the volume where HIFU therapy can be delivered. Bowel loops present a particular problem because of bowel gas bubbles and hard particles which may cause reflection or absorption of ultrasound energy, potentially leading to thermal damage and even bowel perforation. Most commonly used techniques for bowel repositioning are bladder and/or rectum filling but these are not always sufficient to reposition the bowel loops. With more efficient bowel repositioning technique, the number of eligible patients for MR-HIFU treatment could be increased, and therapy efficacy be improved in cases where bowel loops limit the treatment window. A wedged exterior gel pad was used in two patients presented with in total of four symptomatic fibroids undergoing MR-HIFU treatment when bladder and/or rectum filling was not sufficient to reposition the bowel loops. No severe adverse effects were observed in these cases. The non-perfused volume ratios (NPVs) immediately after treatment were 86% and 39% for the first patient, and 3% for the second patient. Our preliminary experience suggests that the use of a wedged gel pad during MR-HIFU treatment could be an effective tool to manipulate the bowels in cases where the bladder and/or rectum filling is not sufficient to reposition the bowel loops. A wedged gel pad could also be used in other situations to achieve better treatment coverage to the uterine fibroid.

1 January 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
CWCameron Wright
Cameron Wright
PMPietari Mäkelä
Pietari Mäkelä
MAMikael Anttinen
Mikael Anttinen
TSTeija Sainio
Teija Sainio
PBPeter J. Boström
Peter J. Boström
RSRoberto Blanco Sequeiros
Roberto Blanco Sequeiros
Fiducial markers improve accuracy in external beam radiation therapy (EBRT) for treatment of prostate cancer (PCa). However, many patients recur after EBRT necessitating additional treatment, such as MR-guided transurethral ultrasound ablation (TULSA). Residual markers may compromise TULSA through ultrasound field distortions and generation of local susceptibility artifacts. The objective was to investigate how markers affect the ablation outcome during clinical TULSA treatments. A retrospective analysis was performed on nine patients with radiorecurrent PCa and residual markers who received TULSA. The MR susceptibility artifact was quantified as a function of marker type, size and orientation, in particular for thermometry. The spatial distribution of markers inside the prostate was recorded, and the resulting impact on the thermal dose was measured. The thermal dose measurements were directly compared to the residual enhancing prostatic tissue observed on the immediate and control post-TULSA contrast enhanced (CE) image. Successful thermal dose accumulation to the target boundary occurred for 14/20 (70%) of markers, confirmed with CE imaging. Gold markers situated simultaneously close to the urethra (≤12 mm) and far from the target boundary (≥13 mm) reduced the ultrasound depth of heating. Nitinol markers produced large, hypointense artifacts that disrupted thermometry and compromised treatment. Artifacts from gold markers were less pronounced, but when located near the target boundary, also affected treatment. Marker composition, orientation and location inside the prostate can all potentially impact treatment outcome. Proper patient selection through detailed MRI screening is critical to ensure successful radiorecurrent PCa treatment outcomes with TULSA.

1 January 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
TSTeija Sainio
Teija Sainio
JSJani Saunavaara
Jani Saunavaara
GKGaber Komar
Gaber Komar
SOSaara Otonkoski
Saara Otonkoski
KJKirsi Joronen
Kirsi Joronen
RSRoberto Blanco Sequeiros
Roberto Blanco Sequeiros
The aim of this study was to assess the feasibility of T2 relaxation time in predicting the immediate technical outcome i.e., nonperfused volume ratio (NPVr) of magnetic resonance-guided high-inten...

28 May 2025 in BJU International
Verified
Journal Article
Open access
AVAntti Viitala
Antti Viitala
MAMikael Anttinen
Mikael Anttinen
PMPietari Mäkelä
Pietari Mäkelä
HPHeikki Pärssinen
Heikki Pärssinen
PNPertti Nurminen
Pertti Nurminen
PBPeter J. Boström
Peter J. Boström
Objectives: To evaluate the safety and efficacy of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). Patients and Methods: This prospective, single‐centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate‐specific antigen (PSA) levels, and validated questionnaires at baseline and 3‐month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien–Dindo classification. Results: The median patient age at treatment was 67 years. During the 12‐month post‐TULSA follow‐up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s ( P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s ( P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 ( P < 0.001), and IPSS quality of life score improved from 4 to 1 ( P < 0.001). The 26‐item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 ( P < 0.001), and urinary incontinence scores improved from 86 to 100 ( P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow‐up. Conclusions: Transurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long‐term outcomes and validation in larger cohorts remain essential.